At Southern RNA, we provide integrated contract development and manufacturing services designed specifically for RNA therapeutics and vaccine programmes. As an Australian-based mRNA CDMO, we partner with biotechnology companies, research institutes and clinical developers to translate innovation into high-quality, regulatory-ready material.
Researchers and biotechnology companies use Southern RNA’s plasmid DNA and mRNA production platforms to generate high-quality raw materials for gene expression studies, vaccine design, and therapeutic candidate evaluation. This includes capped, modified mRNA and traceable pDNA templates for in vitro and in vivo applications.
Preclinical programs benefit from scalable production of research and GMP-aligned grade nucleic acids as they advance toward translational milestones. Southern RNA’s process development and analytical services help ensure consistency, purity, and suitability for later stages of evaluation.
Biopharmaceutical developers preparing for early clinical studies (FIH through Phase I/II) rely on Southern RNA’s GMP-capable workflows to produce clinical-appropriate drug substance. This includes plasmid DNA for viral vector manufacturing and mRNA for vaccines or cell therapies, with quality documentation supporting regulatory needs.
Scientists and quality teams use Southern RNA’s comprehensive analytical platform to characterise nucleic acid products, support method development, and validate stability and release assays. This underpins confidence in product performance and regulatory compliance throughout development.
Southern RNA provides plasmid DNA and mRNA services, merging flexible manufacturing with advanced analytics. Our team supports scalable, high-quality nucleic acid production for therapeutic programs.
We provide plasmid DNA (pDNA) and mRNA production using flexible platforms that deliver high-quality R&D and GMP- aligned grade materials at scalable volumes.
We provide a comprehensive nucleic acid analytical platform, supported by the deep expertise and experience of our multidisciplinary scientific team.
Integrated mRNA manufacturing and analytical testing processes designed to scale efficiently from early development to clinical readiness.
Our FAQ section addresses the most common technical and compliance queries, providing clarity on our capabilities, processes, and quality systems.
Yes, our facilities produce GMP-aligned and clinical-grade mRNA and plasmid DNA suitable for early-phase trials.
We follow GMP-aligned processes, robust documentation, and quality oversight to meet regulatory expectations and support submissions.
We offer flexible production from milligram-scale research material to multi-gram clinical-grade batches.
Yes, our in-house analytical team supports identity, purity, impurity profiling, and stability testing across all projects.
Absolutely. Our team develops reproducible processes for smooth transition from research-scale to GMP-aligned clinical production.
